Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
The Federal Circuit revived Amarin's heart drug patent lawsuit against Hikma, stating that Hikma's actions may have induced doctors to prescribe a drug violating Amarin's patents. This decision comes after the court reversed a preliminary injunction for trade secret misappropriation and waded into Article III standing in patent cases. Additionally, the court ruled that Section 285 does not allow recovery of fees incurred in IPRs or extend to counsel.
Federal Circuit: Section 285 Does Not Permit Recovery of Fees Incurred in IPRs Nor Does it Extend to Counsel https://t.co/M8Lxrrncqn | by @akin_gump
Federal Circuit: Reverses Motion to Dismiss—Generic Manufacturer’s Label Combined with its Expansive Public Statements Plausibly Induced... https://t.co/A8MXBggZ4Q | by @akin_gump
Employment Law This Week Episode 350 - Spilling Secrets: Protecting Trade Secrets with E-Discovery [Video, Podcast] https://t.co/zHDXHekDxd #employmentlaw #tradesecrets #ediscovery @EpsteinBecker https://t.co/4o3hkZpFxp
